To evaluate the bladder preservation strategy used at our institution for muscle-invasive bladder cancer (MIBC) in patients undergoing chemoradiotherapy.
INTRODUCTION AND OBJECTIVES: Over the last decades, several studies, including our group have shown that the use of trimodal therapy consisting of transurethral bladder resection followed by concomitant chemotherapy and radiation therapy results in comparable outcomes to radical cystectomy, considered the gold standard for muscle invasive bladder cancer (MIBC). We present our oncologic outcomes for tetra-modal bladder preservation technique, which include tri-modal therapy followed by selective intra-arterial infusion of chemotherapeutics.
METHODS: We performed an analysis of our prospectively maintained IRB approved database of multimodal bladder preservation technique. Our tetra-modality therapy consisted of complete resection of the tumor, chemotherapy and radiation therapy followed by dual balloon occluded intra-arterial infusion of chemotherapeutics -OMC regimen. We included all cases from August 2009 until December 2015 with at least 6 months of follow up. We evaluated oncologic outcomes based on T-stage, grade, lymph node status, age, sex, and presence of hydronephrosis. All data was analyzed using SPSS ver15.
RESULTS: Four-hundred ten MIBC patients were enrolled in the study (median age 67 years, 78.8% male, ECOG performance status 0/1/2 100.0%, T-stage II/III/IV 67.1%;23.1%; 9.8%). , approximately 20% of patients treated with PC have been reported to ultimately require radical cystectomy (RC) for disease recurrence. The outcomes for these patients have not been well described to date. We therefore evaluated perioperative and oncologic outcomes of patients undergoing RC after PC for UC. METHODS: We identified 61 patients who underwent RC at our institution after prior PC for UC between 1980-2010. These patients were then matched 1:3 to patients undergoing primary RC based on age, pathologic T and N stage, and decade of surgery. Perioperative outcomes were compared between the two groups using descriptive statistics. Cancer-specific (CSS) and overall survival (OS) were evaluated using the Kaplan-Meier method and conditional Cox proportional hazards regression models.
RESULTS: Median age at the time of RC was 67 yrs in both groups (IQR 62, 75) , while 47/61 (77%) RC after PC and 151/181 (83.4%) primary RC patients were male. Median time from PC to RC was 1.5 years (IQR 0.6, 4.4) . Median Charlson comorbidity index was 2 for both groups (IQR 2, 8) . Estimated blood loss was significantly higher among patients undergoing RC after PC compared to primary RC (median 1000 cc vs 700 cc; p¼0.001), although there was no difference in operative time (median 322 min vs 292 min; p¼0.17) or length of stay (median 10 vs 11 days; p¼0.27). Similarly, there was no difference in either minor (Clavien 1-2) (49.2% vs 44.8%; p¼0.71) or major (Clavien 3-5) (9.8% vs 8.3%; p¼0.55) perioperative complications between the RC after PC and the RC alone groups. Median follow-up after RC was 6.0 years (IQR 1.5, 15.6), during which time 204 patients died, including Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e249 95 who died of UC. Five-year CSS was significantly worse for patients who underwent RC after PC versus primary RC (58% vs 67%; p¼0.02; HR 1.8; 95% CI 1.1, 3.0), while no significant difference in 5-year OS was noted (51% vs 54%; p¼0.42; HR 1.2; 95% CI 0.8, 1.7). CONCLUSIONS: Patients who underwent RC for recurrent UC after prior PC had similar perioperative outcomes to stage-matched patients undergoing primary RC. However, such patients were noted to be at a higher risk of subsequently dying from bladder cancer. These data may be used in counseling patients considering PC as initial treatment for invasive UC, as well as for consideration of adjuvant therapy after RC following PC.
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MP21-07 SELECTION EFFECTS MAY EXPLAIN SMOKING-RELATED OUTCOME DIFFERENCES AFTER RADICAL CYSTECTOMY
Michael Froehner*, Rainer Koch, Matthias H€ ubler, Ulrike Heberling, Vladimir Novotny, Stefan Zastrow, Manfred P. Wirth, Dresden, Germany INTRODUCTION AND OBJECTIVES: The impact of smoking on mortality in patients with bladder cancer is subject to controversies. METHODS: We investigated 1000 patients who consecutively underwent radical cystectomy between 1993 and 2013. Proportional hazard models for competing risks were used to study combined effects of variables on bladder cancer and competing mortality.
RESULTS: The median follow-up in the survivors was 6.6 years; 331 patients had died from bladder cancer, 178 from non-cancer or unknown (n¼6) causes and 54 from a second cancer. Compared with non-smokers, current smokers were more frequently male (35.7% versus 12.0%, p<0.0001), younger (63.5 versus 70.5 years, p<0.0001), had a lower body mass index (26.2 versus 27.1 kg/m2, p<0.0001) and suffered less frequently from cardiac insufficiency (12.7% versus 19.3%, p¼0.0129). In current smokers there was a trend towards lower bladder cancer and higher competing mortality compared with nonsmokers. In the multivariable analysis, current smoking was no predictor of bladder cancer mortality (hazard ratio, HR, in the full model 0.76, p¼0.0687) but of competing mortality (HR in the optimal model 1.62, p¼0.0044).
CONCLUSIONS: This study did not confirm adverse bladder cancer-related outcome in current smokers after radical cystectomy. With a younger mean age and a male predominance, current smokers showed a trend towards lower bladder cancer mortality that was eventually neutralized by increased competing mortality illustrating that selection effects may explain some smoking-related outcome differences after radical cystectomy. ASA score, TNM-classification and type of urinary diversion. We recorded the presence of urologic devices before RC, neo-adjuvant chemotherapy, previous radiotherapy, prolonged steroids therapy before RC, microbiological urine and blood cultures. UTI was diagnosed according to EAU/ESIU definitions. Primary objective was to analyze the type and length of antibiotic therapy (AB), the percentage and severity of UTIs after RC, the responsible bacteria and their AB sensitivity. We recorded the frequency of CT-scans and invasive procedures after RC and 30-days-readmission rate.
RESULTS: We analyzed 217 cases of RC. Median length of hospital stay was 13 days (IQR 11-20.5) with 9.2% of the patients still in hospital after 30 days. 30-days-readmission rate was 16.1%. The most frequent AB was a combination of metronidazole (98.2%) with a cephalosporin (89.9%). The median of days of AB administration after RC was 7 days . After cessation of the first AB therapy, additional antibiotics were used in 51.6% of the patients. The overall number of UTIs was 42 (19.4%): 9.7% pyelonephritis, 7.8% urosepsis, 1.8% uroseptic shock. Enterococcus spp. was the most frequently isolated bacteria in urine (25.7%) and in blood (42.9%). Enterococcus showed, as awaited, a cephalosporin (100%) and gentamicine (90%) resistance but also a 100% resistance to ciprofloxacin. In univariate logistic regression analysis, age (odds ratio (OR)¼0.94; p¼0.001), continent derivation (OR¼4.36; p<0.001), neoadjuvant chemotherapy (OR¼3.07; p¼0.044) and the presence of any urologic device before surgery (OR¼0.36; p¼0.013) were correlated with UTI. In multivariate logistic regression analysis only continent derivation was associated to UTI after surgery (OR¼3.16; p¼0.010).
CONCLUSIONS: The UTI rate after RC was 19.4% and in 9.6% of the cases UTI was urosepsis. Continent diversion was the only independent factor associated with a higher risk of UTI but perioperative AB therapy length was not. Enterococci spp. are involved in early infection and not routinely covered by the most common used AB prophylaxes.
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